KPV

What is KPV?

KPV is a tripeptide, just three amino acids: lysine, proline, and valine. It is the tail end (residues 11 to 13) of alpha-MSH, a hormone your body uses to control both inflammation and skin pigmentation. Researchers isolated this fragment because it keeps the anti-inflammatory punch of the parent hormone without the skin-darkening effect. It is a research compound, studied mostly in cell cultures and animal models of gut and skin inflammation, and no approved human product uses it.

How KPV works

KPV calms inflammation from inside the cell. It blocks the nuclear translocation of NF-kB, the master switch that turns on inflammatory cytokine genes, and it also dampens MAP-kinase signaling. Both effects show up at low, nanomolar concentrations in lab studies. There is a useful quirk to its size: because it is only three amino acids, KPV can hitch a ride on the PepT1 transporter that intestinal cells use to absorb small peptides. That is part of why it draws interest for gut inflammation and oral delivery specifically.

What the research shows

Most of the evidence is preclinical. In mouse models of colitis, KPV reduced inflammation and tissue damage, and it worked in immune cells that do not carry the classic melanocortin receptors, which points to an intracellular route rather than the usual alpha-MSH pathway. Skin and epithelial cell studies lean the same way. The honest gap is that there are no published human clinical trials, so the promising animal and cell data has never been tested in people at any real scale.

Dosage and how it is used

There is no approved or validated human dose. In the research community KPV turns up as an oral capsule, a topical cream, or an injection, and the figures people cite come from anecdote and animal work rather than dose-finding studies. Treat any protocol you see as unproven convention, not medicine.

→ How to reconstitute KPV: calculator, units to draw & storage

Side effects and safety

Because there is almost no human data, the safety picture is mostly theoretical. Short peptides like this tend to be low-toxicity in animal studies, and alpha-MSH fragments have a long research history, but neither of those is the same as a documented human safety record. You are stepping outside anything that has been formally tested for tolerability or long-term use.

• Research depth: limited. Preclinical only, with no published human clinical trials.
• Minimal human safety data. Tolerability at the doses people use is unstudied.
• Not FDA-approved. Legal status varies by jurisdiction; verify it independently.

Frequently asked questions

References

• Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis, 2008.
• Wang W et al. Antifibrotic and anti-inflammatory actions of alpha-melanocytic hormone. Front Endocrinol (PMC7827684), 2021.